EBSEmergent BioSolutions Inc.
Pharmaceutical Preparations
- Revenue
- $743M
- 29% YoY
- Operating margin
- 13.5%
- 229% YoY
- EBITDA
- $196M
- 195800% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.3×
- $450M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear324% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear15% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.1B | $1.0B | $1.0B | $743M | 29% |
| Operating income | $341M | −$170M | −$726M | −$109M | $100M | 192% |
| Net income | $220M | −$212M | −$761M | −$191M | $53M | 128% |
| Operating cash flow | $320M | −$34M | −$206M | $59M | $171M | 191% |
| Capex | $224M | $116M | $52M | $23M | $14M | 40% |
| Stock-based comp | $42M | $45M | $23M | $18M | $16M | 10% |
| Buybacks | $106M | $82M | $0 | $0 | $25M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $146K · 2
- Net
- −$146K
Pay vs performance
No pay-versus-performance disclosure yet.